Company intelligence / Profile preview

SeeMedX

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

SeeMedX submitted a 510(k) premarket notification to the FDA in November 2024 for its non-invasive cardiac monitoring device. The device provides real-time hemodynamic measurements including Zo (fluid status) and cardiac output to enable earlier detection of volume overload and heart failure symptoms compared to traditional methods.

Therapeutic areas: NephrologyCardiovascular
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on SeeMedX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeeMedX.

Explore the full profile